CJC-1295 No DAC / Ipamorelin: Pulsatile Signaling

Preserving the Pulse: The Rationale for Short Half-Life GHRH Analogs

The core principle behind utilizing CJC-1295 (No DAC) in combination with Ipamorelin is the maintenance of pulsatile Growth Hormone (GH) release. This approach seeks to mimic the body's natural physiological rhythm, which is characterized by discrete, high-amplitude bursts of GH secretion.

Unlike long-acting Growth Hormone-Releasing Hormone (GHRH) analogs, which can lead to a sustained, non-physiologic elevation of GHRH levels, the "No DAC" variant of CJC-1295 is selected specifically for its short half-life. This pharmacokinetic profile ensures that the analog rapidly clears from the circulation, allowing the pituitary somatotrophs to return to their basal state shortly after the pulse is triggered.

When CJC-1295 (No DAC) and Ipamorelin are administered together, a powerful, yet naturally-paced, amplification of GH signaling is achieved:

• Ipamorelin (GHS - Growth Hormone Secretagogue) sets the stage by acting on the ghrelin receptor. It raises the basal level of GH secretion by suppressing somatostatin (GH-Inhibiting Hormone) and mildly stimulating GH release. This elevates the responsiveness of the pituitary gland.
• CJC-1295 (No DAC) (GHRH Analog) acts directly on the pituitary GHRH receptor, triggering the sharp, high-amplitude pulse of GH release.

This synergistic mechanism results in a greater total GH output without desensitizing the GHRH receptor.

Why Combine? Avoiding Receptor Downregulation

The combination of a short-acting GHRH analog (CJC-1295 No DAC) and a potent GHS (Ipamorelin) is strategically designed to avoid a phenomenon known as the "bleeding" effect.

Mechanism of Action

Component

Effect on GH Release

GHRH Receptor Agonist (Short-acting)

CJC-1295 (No DAC)

Triggers the pulse (High amplitude, short duration)

Ghrelin Receptor Agonist (GHS)

Ipamorelin

Raises the basal level and amplifies the pulse

Consequences of Continuous Stimulation

Studies focused on maintaining natural endocrine function must prioritize the integrity of the pituitary gland's receptors. Continuous, supra-physiological stimulation of the GHRH receptor, often associated with long-acting analogs, can lead to:

1. Receptor Desensitization: The GHRH receptors become less responsive over time.
2. Receptor Downregulation: The number of available GHRH receptors on the somatotroph cell surface is reduced.
3. Abolishment of Pulsatility: The natural, necessary peaks and troughs of GH release are flattened, leading to chronic, low-level GH elevation which is less effective than the natural pulsatile pattern.

By utilizing CJC-1295 (No DAC), the system is allowed a recovery period after each pulse, maintaining the natural rhythm and maximizing total GH output while actively working to prevent receptor downregulation. This is crucial for long-term research focused on physiological efficacy.

Product Specifications

This combination is supplied under strict quality control standards suitable for sensitive research applications.

Specification Category

Detail

Purity

High Purity Research Grade

Preservation

Lyophilized via cryodesiccation

Storage (Unreconstituted)

Recommended at -20°C (Freezer)

Storage (Reconstituted)

Recommended at 2°C – 8°C (Refrigerator)

Presentation

Crystalline white powder

Testing

Confirmed by Mass Spectrometry and HPLC

Peptide Structure

CJC-1295 (No DAC) and Ipamorelin (Specific sequences confirmed)

Research Considerations: Administration and Dosing

Effective utilization of this pulsatile signaling pair requires timed administration protocols to fully capitalize on the short half-life of CJC-1295 (No DAC).

Recommended Protocol Rationale

The primary goal is to simulate the body's natural GH pulses, which typically occur multiple times throughout the day, with the largest pulse often occurring shortly after the onset of deep sleep.

Aspect

Rationale for Pulsatile Protocol

Timing

Administrations should be timed to avoid saturating the receptors, typically allowing 3-4 hours between injections to ensure the CJC-1295 (No DAC) has fully cleared.

Pre-Sleep Dose

The largest dose is often administered 30-60 minutes before the onset of sleep to coincide with the largest natural GH pulse, enhancing overall nocturnal secretion.

Meal Timing

Administration should ideally occur on an empty stomach (or 2 hours after a meal) to minimize interference from elevated glucose or free fatty acid levels, both of which can blunt GH release.

Handling and Reconstitution

The peptides are supplied in lyophilized (freeze-dried) form to ensure maximum stability and shelf-life. Proper reconstitution is critical for maintaining peptide integrity.

1. Reconstitution Fluid: Use bacteriostatic water for injection.
2. Technique: Gently inject the reconstitution fluid down the side of the vial. Do not spray directly onto the powder.
3. Mixing: Do not shake the vial. Gently swirl the vial until the white powder is completely dissolved.

Note: Once reconstituted, the peptide solution is significantly less stable. It must be refrigerated and should be utilized within Date to Date for optimal activity.

References and Further Study

For detailed technical specifications and purity analysis, please consult the accompanying Certificate of Analysis (File) and the detailed Material Safety Data Sheet (File).

Any further queries regarding research protocols or product technical details should be directed to the Research Support Team at Person.

[A detailed chart illustrating the difference between pulsatile and continuous GHRH signaling, showing peaks and troughs for the former and a flat line for the latter]

Safety and Disposal

Used reconstitution fluid vials and syringes should be disposed of in an approved sharps container in accordance with institutional guidelines.

Disclaimer

This product is sold for research purposes only and is not for human consumption, diagnostic, or therapeutic use. Handle with appropriate laboratory safety precautions, including wearing gloves, lab coat, and eye protection. All researchers must comply with all relevant local and federal regulations pertaining to the handling and use of research-grade peptides.